|La Valmy is spot on!
Avacta has all the trappings of a University spin out company.
Lots of promise of jam tomorrow but no solid plan on how to get there.
La Valmy is also right to point out that the Avacta CEO has not delivered on many of his revenue projections.
Therefore,in the very difficult therapeutic sector why are things set to change.
The sideways shift of a failed COO without a replacement in place is also very worrying .|
|I have been having something of a look at AVCT, and, probably heresy to many here, suspect that it will at some stage fit my investment critera.
They have had a long history of over-promising and under-delivering with the same CEO in place. The rather sordid acquisition and placing announced in December 2011 which would end all placings was, of course, followed by another in July 2013 and a much larger one in July 2015, much of which has been spent on shiny new premises, inter alia to impress the customers. The existing business at the time has been sold off or stagnated. So a successful history.
I have no reason to believe that significant revenues will materialise in the near future and as that realization sinks in, so will the realization that it will need more capital. Of course, that will be dressed up as required for their therapeutic targets, in which they have no experience, rather than the lower hanging fruit of diagnostics etc. It strikes me as more sensible to attempt to build a profitable, boring, business first and the perhaps letting rip on the other stuff. The cash they are able to spend on it currently is laughable in the context of big Pharma in any case.
So the view from afar is that they will disappoint and then will possibly be worth picking up when investor interest has faded somewhat. I note that many here were enthusiastic shareholders way before the 'transformational' acquisition. I also note that the company suffers from RNS diarrhoea, and, with even more distaste, that it includes RNS's about paid-for investment research.
A recent poster did mention that success in this sort of investment comes more when the company is actually succeeding. He could well be right.|
|Clearly the market knows well in advance (24 hours) of us "normal shareholders" about RNS messages etc. However the drop in share price does not seem to have any fundamental support or reason. As I mentioned yesterday the drop in share price does not even seem to be linked to any significant share sale.
The strategic update just released confirms everything we know about the company. There are no surprises. I e mailed Alastair Smith and whilst he cannot comment on share movements specifically, he expressed his "frustration" at yesterday's sudden movement and confirmed the steady progress of the company.
Overall I believe the best conclusion is that this is an attempt to manipulate the share price (which often happens for small companies) and the right response is to sit tight and even use it as a buying opportunity|
|Some very stupid comments on here!
With Graig Slater having a reduced role to overseeing Avacta Animal Health (AAH), it will be interesting to see who becomes Chief Operating Officer responsible for the commercial and operational development of the Group (or indeed Avacta Life Sciences).
Btw, I still think AAH has a lot of unrealised potential, especially in terms of using Affimers. It's market is unregulated and offers a relatively quick route to producing tests that demonstrate out-performance......differentiating AAH, but ultimately highlighting the effectiveness of Affimers.|
|Why no comment from the company,or is Wan the company?!|
|Jeeze no please anything but that...|
|We await Wan's comments with interest.|
|Yet Finncap yesterday placed a value on AVACTA of 200p in 12 months!
Avacta Group PLC (LON:AVCT) Issued With ‘CorporateR17; Rating At FinnCap
By Warren Smith / in UK Broker Ratings / on Wednesday, 30 Nov 2016 02:02 PM / 0 Comments
Following an update released by analysts at finnCap on Tuesday the broker has now set a ‘CorporateR17; rating on shares of Avacta Group PLC (LON:AVCT) with a price target of 200.
On Tuesday finnCap reiterated its target for shares of Avacta Group PLC as ‘CorporateR17; recommending a target price of 200 for investors; potentially meaning there is an increase of 129.75% from Avacta Group PLC’s share price of 87.05.
Avacta Group PLC has 68,287,000 shares currently held by shareholders which currently trade around the 87.05 mark which totals Avacta Group PLC’s market capitalisation to 59.44M GBP.
12 Month Share Chart For Avacta Group PLC
In the duration of 12 months Avacta Group PLC’s share price has increased by 0% to 87.05 from 0.00.
The business has a 50 day moving average of 89.99 and a 200 day moving average of 95.94 whilst the 52 week high shares of Avacta Group PLC have reached is 134.5 and the 52 week low is 83.02.
Avacta Group plc is the developer of Affimer bio therapeutics and research reagents. The Company’s segments include Animal Health, which provides tools and contract services to assist diagnosis of conditions in animals to enable treatment for veterinarians, and Life Sciences, which provides reagents and arrays for diagnostics, drug and biomarker discovery in biotech research and development. The Company’s in-house programs include Oncology, which is engaged in developing combination therapies combining multiple immune checkpoint inhibitors by making bi- and tri-specific Affimer constructs, and Blood clotting disorders, which allows Affimer therapeutics to generate the modulate blood clot formation with the potential for anti-thrombotic, as well as wound healing therapies. It focuses on its Affimer technology, which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and develoPment|
|A broker nearby my work says a RNS has been issued. Something to do with Affinity Technology. I'm confused. Does this mean anything to anyone? Not my confusion BTW but regards to an RNS and Affinity.
Where's Wan when we need him?
|The board seem to be asleep at the wheel!|
|10% in a day, and 50% off the highs, deserves some executive commentary in my view.|
|if you look at the share trades it seems to have continued as normal then the share price fell a few p even though only a small number of trades was going through and then a sell order came through for 30000.. though the share price was dropping by then.. then subsequent partial rebound...
either someone knows something we don't eg failure to sign a contract or even a hiccup with the Moderna deal or else its just a random fluctuation... no news on web site|
|A(nother) buying opportunity? or something more sinister?|
|What's happened? Down 10.5p ! I feel ill !|
|Another very encouraging technology update today from Avacta -
23 November 2016
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Avacta demonstrates key performance benefits of Affimer technology for affinity separation
full release -
I have been a way for a few weeks and further note that Avacta's website has been updated to include tabs for the different (and expanding) application areas, they are informative and also include videos with Alastair Smith, Matt Johnson and Amrik Basran -
Dec2000 has got it right.
The share price will remain low until the Avacta Board does a deal that the market likes not just bits of information about jam tomorrow.
The market knows what it wants and until then let's not expect too much.|
|I think it is about timing and the requirement of evidence over hope.
On the therapeutic side, we have only evidence in one of six therapeutic programmes, and even then , although there have been encouraging preliminary results in the in-house PDL1 immuno oncology programme, we do not know a lot.. Yes we have been told there was significant anti tumour activity but we do not know how significant! The first real results in an efficacy study in man are perhaps 3 years away... In all six programmes.
On the Rx Dx side all we know is that there are perhaps a dozen companies evaluating Affimers for various uses, whether as diagnostics or affinity separations or whatever. But again looking at the Avacta presentation, they do not foresee signing deals until some time in 2017 with revenue coming perhaps in 2018. The latest Hardman forward view on revenue would also support that kind of timescale.
So whereas I am a huge fan of the company, I think it is only realistic to assume revenue and hence share price growth is some time away. And I note in my reading one of the best investors of all time when he ran the Magellan Fund, was quoted as saying one is better to invest in these small companies at stage 2 when growth is already apparent rather than at the beginning before growth has started!|
|Anybody got any ideas about why the falling price after all the good news stories that we've had? The only reason I can think of is the US election for some reason, but I can't see why.|
|Having kept a distant eye on AVCT for many years, I'm reluctantly (hard experience with numerous AIM medi/pharma/bios says "don't!") considering buying a few. Currently i'm only holding HZD in the sector, (less risk as self funding) needless to say at a loss, but i remain keen. Its CEO is very good. Links below are for my education.
|The Drewster...You beat me to it! In particular it underscores what I implied further above -
"Of particular interest, Dr Brentjens was a scientific co-founder of Juno Therapeutics (JUNO), a NASDAQ-listed biotech company that is developing cell-based cancer immunotherapies based on CART-T cell technologies, with eight drug candidates currently in clinical trials. Therefore, the fact that this specialist is willing to enter a research collaboration involving Affimers in his area of expertise is highly significant."|
|Apologies if already posted yesterday:
|Tremendously exciting. The specificity of the Affimers binding CD19 will, when proven, transform cancer therapy options and open A LOT of doors (or have companies banging our doors down).|
|Just to confirm and add a bit more context to my comment above -
CAR T cell therapy is currently being evaluated in the clinic at MSK for certain types of leukemia and lymphoma. In this approach, T cells are genetically engineered to recognize a protein called CD19, which is found on the surface of blood cells called B cells. In the largest study reported so far, for adult patients with B cell acute lymphoblastic leukemia — a rapidly progressing form of blood cancer — a report published by MSK researchers last year found that 88 percent of patients responded to the therapy. In late 2014, the US Food and Drug Administration granted MSK Breakthrough Therapy Designation for its CD19 CAR therapy.
|Applications for Affimers knows no bounds.
02 November 2016
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Avacta announces CAR-T cell therapy research collaboration with major US cancer centre
· CAR-T cell therapy is a major new area of cancer therapy that has attracted $billions of investment in the past few years
· Affimer technology will potentially provide significant advantages over antibody fragment technology currently used in CAR-T cell modification
· Proof-of-concept study with major US cancer centre has the potential to open up highly valuable licensing and partnering opportunities
full release -